Add as a preferred source on GoogleAtea Draws $65 Million From Hercules Facility for Hepatitis C Program
The draw came from a facility of up to $200 million. Atea expects its planned operations to be funded into mid-2028.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) drew $65 million from a Hercules credit facility, adding financing to its hepatitis C program as it targets a potential U.S. application for mid-2027, contingent on trial results.
The draw came under a facility of up to $200 million. Atea expects its planned operations to be funded into mid-2028.
The program centers on bemnifosbuvir and ruzasvir (BEM/RZR), an investigational combination regimen for hepatitis C virus (HCV). Atea expects top-line results from its C-FORWARD study in early 2027. A U.S. new drug application (NDA) is targeted for mid-2027 if those results are positive.
C-BEYOND, an earlier study, met its primary and secondary endpoints. C-BEYOND reported a 94% SVR rate for BEM/RZR. The results showed statistical non-inferiority to sofosbuvir/velpatasvir (SOF/VEL).
Atea projects peak annual U.S. net sales above $700 million for BEM/RZR. The company estimates U.S. HCV net sales were about $1.3 billion in 2025.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.